Commitment to Reducing Animal Use

RESOLVED, that the Board report to shareholders on the justification for specifically contributing to the advancement of animal-based testing while publicly promoting an Animal Care Policy that commits to the advancement of non-animal based test methods.

Supporting Statement:

Pfizer has published its Guidelines and Policy on Laboratory Animal Care (its “Animal Care Policy”) on the Company Web site which asserts that Pfizer is committed to the “principles known as the 3Rs of animal research.” It states that the 3Rs include i) the “refinement of the use of research animals to use less painful or the least invasive procedures whenever possible”; ii) the “reduction of the numbers of animals used in each study to the absolute minimum necessary to obtain valid results”; and iii) the “replacement of animal experiments with non-animal experiments such as mathematical models, computer simulations, and in vitro biological systems whenever appropriate.”

On July 29, 2004, it was reported in the Financial Times of London that Pfizer and two other pharmaceutical companies¹ donated four million pounds (£4M) to British universities to promote medical research and training specifically using animals, stating that “the donation was part of a greater willingness by their industry to back animal testing publicly.”

Affirmatively supporting and promoting animal testing is wholly inconsistent with Pfizer’s purported policy of reducing, refining, and replacing animal-based methods. Moreover, in the Proxy Materials for the 2004 annual meeting of shareholders, the Company relied on its commitment to the Animal Care Policy in an effort to convince shareholders to vote against a Shareholder Proposal Relating to In Vitro Testing. That Proposal sought support for five

¹ The other two pharmaceutical companies are AstraZeneca and GlaxoSmithKline.
validated non-animal test methods. The Company opposed the Proposal, arguing that Pfizer was fully committed to its Animal Care Policy which rendered the Proposal unnecessary and stating that “Pfizer has always supported the use of in vitro alternatives …” These claims cannot be reconciled with the decision to commit significant funds for the purpose of affirmatively promoting and publicly advancing animal testing and training graduate students to conduct animal experiments.

We urge our fellow shareholders to support this Resolution and help make Pfizer’s actions consistent with the Company’s Animal Care Policy.